NAFLD and thyroid function: pathophysiological and therapeutic considerations

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · see citing works

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836 · see citing works

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works

Thyroid Hormone Regulation of Metabolism

Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00030.2013 · Cited by 2,421 · see citing works

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis

Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235 · see citing works

A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis

Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · see citing works

Global epidemiology of hyperthyroidism and hypothyroidism

Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552 · see citing works

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · see citing works

Treatment of NAFLD with diet, physical activity and exercise

Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347 · see citing works

Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics

Pοlyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2018) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,221 · see citing works

The integrative biology of type 2 diabetes

Roden, M., & Shulman, G. I. (2019) · Nature · doi:10.1038/s41586-019-1797-8 · Cited by 1,167 · see citing works

Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association

Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053 · see citing works

NAFLD and diabetes mellitus

Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002 · see citing works

The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments

Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850 · see citing works

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · see citing works

Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease

Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771 · cited 1× · see citing works

Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review

White, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766 · see citing works

Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00523-4 · Cited by 757 · see citing works

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

Athyros, V. G., Tziomalos, K., Gossios, T. D., Griva, T., Anagnostis, P., Kargiotis, K., Pagourelias, E. D., Theocharidou, E., Karagiannis, A., & Mikhailidis, D. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61272-x · Cited by 685 · see citing works

Direct effects of thyroid hormones on hepatic lipid metabolism

Sinha, R. A., Singh, B. K., & Yen, P. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.10 · Cited by 665 · see citing works

Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study

Zaharia, O. P., Strassburger, K., Strom, A., Bönhof, G. J., Karusheva, Y., Antoniou, S., Bódis, K., Markgraf, D. F., Burkart, V., Müssig, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30187-1 · Cited by 600 · see citing works

Calorie restriction with or without time-restricted eating in weight loss

Liu, D., Huang, Y., Huang, C., Yang, S., Wei, X., Zhang, P., Guo, D., Lin, J., Xu, B., Li, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2114833 · Cited by 516 · see citing works

Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review

Hashida, R., Kawaguchi, T., Bekki, M., Omoto, M., Matsuse, H., Nago, T., Takano, Y., Ueno, T., Koga, H., George, J., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.023 · Cited by 509 · see citing works

Radiologic evaluation of nonalcoholic fatty liver disease

Lee, S. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7392 · Cited by 427 · see citing works

Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial

Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360 · see citing works

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Hartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care · doi:10.2337/dc19-1892 · Cited by 351 · see citing works

Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans

Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330 · see citing works

The Coronary Drug Project

(1972) · JAMA · doi:10.1001/jama.1972.03200070084015 · Cited by 317 · see citing works

Non-alcoholic fatty liver disease across the spectrum of hypothyroidism

Chung, G. E., Kim, D., Kim, W. K., Yim, J. Y., Park, M. J., Kim, Y. J., Yoon, J., & Lee, H.-S. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.027 · Cited by 302 · see citing works

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299 · see citing works

Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis

Apostolopoulou, M., Gordillo, R., Koliaki, C., Gancheva, S., Jelenik, T., De Filippo, E., Herder, C., Markgraf, D., Jankowiak, F., Esposito, I., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1318 · Cited by 284 · see citing works

A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor

Chiellini, G., Apriletti, J. W., Yoshihara, H. A. I., Baxter, J. D., Ribeiro, R. C. J., & Scanlan, T. S. (1998) · Chemistry & Biology · doi:10.1016/s1074-5521(98)90168-5 · Cited by 278 · see citing works

Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index

Erion, M. D., Cable, E. E., Ito, B. R., Jiang, H., Fujitaki, J. M., Finn, P. D., Zhang, B., Hou, J., Boyer, S. H., van Poelje, P. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702759104 · Cited by 273 · see citing works

Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists

Sinha, R. A., Bruinstroop, E., Singh, B. K., & Yen, P. M. (2019) · Thyroid · doi:10.1089/thy.2018.0664 · Cited by 272 · see citing works

Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism

Sinha, R. A., Singh, B. K., & Yen, P. M. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.07.001 · Cited by 241 · see citing works

An assessment by the Statin Liver Safety Task Force: 2014 update

Bays, H. E., Cohen, D. E., Chalasani, N., & Harrison, S. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.02.011 · Cited by 232 · see citing works

Nonalcoholic fatty liver disease in women with polycystic ovary syndrome

Paschou, S. Α., Pοlyzos, S. A., Anagnostis, P. G., Goulis, D. G., Kanaka‐Gantenbein, C., Lambrinoudaki, I. V., Georgopoulos, N. A., & Vryonidou, A. (2019) · Endocrine · doi:10.1007/s12020-019-02085-7 · Cited by 231 · see citing works

Metabolic Effects of Thyroid Hormone Derivatives

Moreno, M., de Lange, P., Lombardi, A., Silvestri, E., Lanni, A., & Goglia, F. (2008) · Thyroid · doi:10.1089/thy.2007.0248 · Cited by 226 · see citing works

Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet—a randomised controlled trial

Holmer, M., Lindqvist, C., Petersson, S., Moshtaghi-Svensson, J., Tillander, V., Brismar, T. B., Hagström, H., & Stål, P. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100256 · Cited by 224 · see citing works

Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam study

Bano, A., Chaker, L., Plompen, E. P. C., Hofman, A., Dehghan, A., Franco, O. H., Janssen, H. L. A., Murad, S. D., & Peeters, R. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1300 · Cited by 209 · see citing works

Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist #

Cable, E. E., Finn, P. D., Stebbins, J. W., Hou, J., Ito, B. R., van Poelje, P. D., Linemeyer, D. L., & Erion, M. D. (2008) · Hepatology · doi:10.1002/hep.22572 · Cited by 206 · see citing works

Overt and Subclinical Hypothyroidism

Khandelwal, D., & Tandon, N. (2011) · Drugs · doi:10.2165/11598070-000000000-00000 · Cited by 199 · see citing works

The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans

Berkenstam, A. L., Kristensen, J. D., Mellström, K., Carlsson, B., Malm, J., Rehnmark, S., Garg, N. K., Andersson, C., Rudling, M. J., Sjöberg, F., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705286104 · Cited by 191 · see citing works

Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis

Kim, D., Kim, W., Joo, S. K., Bae, J. M., Kim, J. H., & Ahmed, A. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.08.014 · Cited by 191 · see citing works

Thyroid hormone signaling and the liver

Ritter, M. J., Amano, I., Hollenberg, A. N., et al. (2020) · Hepatology · doi:10.1002/hep.31296 · Cited by 188 · see citing works

Thyroid hormone-related regulation of gene expression in human fatty liver.

Pihlajamäki, J., Boes, T., Kim, E.-Y., Dearie, F., Kim, B. W., Schroeder, J., Mun, E., Nasser, I., Park, P. J., Bianco, A. C., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0212 · Cited by 164 · see citing works

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD

Chavez, C. P., Cusi, K. J., & Kadiyala, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab578 · Cited by 163 · see citing works

Effects of the Thyroid Hormone Receptor Agonist GC-1 on Metabolic Rate and Cholesterol in Rats and Primates: Selective Actions Relative to 3,5,3′-Triiodo- l -Thyronine

Grover, G. J., Egan, D. M., Sleph, P. G., Beehler, B. C., Chiellini, G., Nguyen, N.-H., Baxter, J. D., & Scanlan, T. S. (2004) · Endocrinology · doi:10.1210/en.2003-0973 · Cited by 161 · see citing works

TSH stimulates leptin secretion by a direct effect on adipocytes

Menendez, C. E. E. A., Baldelli, R., Camiña, J. P., Escudero, B., Peino, R., Diéguez, C., & Casanueva, F. F. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1760007 · Cited by 158 · see citing works

Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Mantovani, A., Nascimbeni, F., Lonardo, A., Zoppini, G., Bonora, E., Mantzoros, C. S., & Targher, G. (2018) · Thyroid · doi:10.1089/thy.2018.0257 · Cited by 154 · see citing works

Thyroid hormone receptor and ERRα coordinately regulate mitochondrial fission, mitophagy, biogenesis, and function

Singh, B. K., Sinha, R. A., Tripathi, M., Mendoza, A., Ohba, K., Sy, J. A. C., Xie, S. Y., Zhou, J., Ho, J. P., Chang, C.-Y., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aam5855 · Cited by 145 · see citing works

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

Sjouke, B., Langslet, G., Češka, R., Nicholls, S. J., Nissen, S. E., Öhlander, M., Ladenson, P. W., OLSSON, A. G., Hovingh, G. K., & Kastelein, J. J. P. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70006-3 · Cited by 142 · see citing works

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

Pοlyzos, S. A., Kang, E. S., Boutari, C., Rhee, E., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154203 · Cited by 141 · see citing works

Activation of thyroid hormone receptor‐β improved disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis

Kannt, A., Wohlfart, P., Madsen, A. N., Veidal, S. S., Feigh, M., & Schmoll, D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15427 · Cited by 140 · see citing works

3,5‐Diiodo‐ <scp>L</scp> ‐thyronine powerfully reduces adiposity in rats by increasing the burning of fats

Lanni, A., Moreno, M., Lombardi, A., De Lange, P., Silvestri, E., Ragni, M., Farina, P., Baccari, G. C., Fallahi, P., Antonelli, A., et al. (2005) · The FASEB Journal · doi:10.1096/fj.05-3977fje · Cited by 134 · see citing works

Large-scale manipulation of promoter DNA methylation reveals context-specific transcriptional responses and stability

de Mendoza, A., Nguyen, T. V., Ford, E., Poppe, D., Buckberry, S., Pflueger, J., Grimmer, M., Stolzenburg, S., Bogdanović, O., Oshlack, A., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02728-5 · Cited by 123 · see citing works

Thyroid hormone receptor β-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats

Villicev, C. M., Freitas, F. R. S., Aoki, M. S., Taffarel, C., Scanlan, T. S., Moriscot, A. S., Ribeiro, M. O., Bianco, A. C., & Gouveia, C. H. A. (2007) · Journal of Endocrinology · doi:10.1677/joe.1.07066 · Cited by 120 · see citing works

Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways

Vatner, D. F., Weismann, D., Beddow, S. A., Kumashiro, N., Erion, D. M., Liao, X.-H., Grover, G. J., Webb, P., Phillips, K. J., Weiss, R. E., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00573.2012 · Cited by 110 · see citing works

Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight

Baxter, J. D., Webb, P., Grover, G. J., & Scanlan, T. S. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.03.008 · Cited by 109 · see citing works

3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet

Mollica, M. P., Lionetti, L., Moreno, M., Lombardi, A., de Lange, P., Antonelli, A., Lanni, A., Cavaliere, G., Barletta, A., & Goglia, F. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.023 · Cited by 109 · see citing works

Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver

Zhang, X., Song, Y., Feng, M., Zhou, X., Lu, Y., Gao, L., Yu, C., Jiang, X., & Zhao, J. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m047654 · Cited by 108 · see citing works

Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica

Aller, R., Fernández‐Rodríguez, C., Iacono, O. L., Bañares, R., Abad, J., Carrión, J. A., García‐Monzón, C., Caballería, J., Berenguer, M., Rodríguez‐Perálvarez, M., et al. (2018) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2017.12.003 · Cited by 108 · see citing works

Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD

Bruinstroop, E., Dalan, R., Cao, Y., Bee, Y. M., Chandran, K., Cho, L. W., Soh, S. B., Teo, E. K., Toh, S.-A., Leow, M. K. S., et al. (2018) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2018-00475 · Cited by 108 · see citing works

Thyroid-stimulating hormone regulates hepatic bile acid homeostasis via SREBP-2/HNF-4α/CYP7A1 axis

Song, Y., Xu, C., Shao, S., Liu, J., Wanjia, X., Xu, J., Qin, C., Li, C., Hu, B., Yi, S., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.006 · Cited by 106 · see citing works

Nonthyrotoxic Prevention of Diet-Induced Insulin Resistance by 3,5-Diiodo-<scp>L</scp>-Thyronine in Rats

de Lange, P., Cioffi, F., Senese, R., Moreno, M., Lombardi, A., Silvestri, E., De Matteis, R., Lionetti, L., Mollica, M. P., Goglia, F., et al. (2011) · Diabetes · doi:10.2337/db11-0207 · Cited by 106 · see citing works

Distinct Dysregulation of Lipid Metabolism by Unliganded Thyroid Hormone Receptor Isoforms

Araki, O., Ying, H., Zhu, X., Willingham, M. C., & Cheng, S.-Y. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0311 · Cited by 105 · see citing works

Thyroid: biological actions of ‘nonclassical’ thyroid hormones

Senese, R., Cioffi, F., de Lange, P., Goglia, F., & Lanni, A. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0573 · Cited by 101 · see citing works

SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

Raj, H., Durgia, H., Palui, R., Kamalanathan, S., Selvarajan, S., Kar, S. S., & Sahoo, J. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i2.114 · Cited by 97 · see citing works

Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases

Chi, H., Tsai, C., Tsai, M.-M., Yeh, C., & Lin, K. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0517-x · Cited by 94 · see citing works

Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: A prospective case-control study

Xu, L., Ma, H., Miao, M., & Li, Y. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.05.025 · Cited by 91 · see citing works

Thyroid Hormone Analogues: An Update

Zucchi, R. (2020) · Thyroid · doi:10.1089/thy.2020.0071 · Cited by 88 · see citing works

Repair-Related Activation of Hedgehog Signaling in Stromal Cells Promotes Intrahepatic Hypothyroidism

Bohinc, B. N., Michelotti, G. A., Xie, G., Pang, H., Suzuki, A., Guy, C. D., Piercy, D. L., Krüger, L., Swiderska‐Syn, M., Machado, M. V., et al. (2014) · Endocrinology · doi:10.1210/en.2014-1302 · Cited by 86 · see citing works

Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality

Kim, D., Vazquez‐Montesino, L. M., Escober, J. A., Fernandes, C. T., Cholankeril, G. T., Loomba, R. S., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000654 · Cited by 78 · see citing works

TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD

Caddeo, A. M., Kowalik, M. A., Serra, M., Runfola, M., Bacci, A., Rapposelli, S., Columbano, A., & Perra, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313105 · Cited by 78 · see citing works

Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study

Lee, K. W., Bang, K. B., Rhee, E., Kwon, H. J., Lee, M. Y., & Cho, Y. K. (2015) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2015.21.4.372 · Cited by 77 · see citing works

Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms

Ferrandino, G., Kaspari, R. R., Spadaro, O., Reyna‐Neyra, A., Perry, R. J., CARDONE, R. L., Kibbey, R. G., Shulman, G. I., Dixit, V. D., & Carrasco, N. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707797114 · Cited by 77 · see citing works

Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?

Lonardo, A., Ballestri, S., Mantovani, A., Nascimbeni, F., Lugari, S., & Targher, G. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.12.014 · Cited by 76 · see citing works

Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus

Kupriyanova, Y., Zaharia, O., Bobrov, P., Karusheva, Y., Burkart, V., Szendroedi, J., Hwang, J., Roden, M., Roden, M., Al‐Hasani, H., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.030 · Cited by 72 · see citing works

Lipid lowering with thyroid hormone and thyromimetics

Angelin, B., & Rudling, M. J. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283402e9c · Cited by 71 · see citing works

Augmented Hepatic and Skeletal Thyromimetic Effects of Tiratricol in Comparison with Levothyroxine

Sherman, S. I., Ringel, M. D., Smith, M. J., Kopelen, H. A., Zoghbi, W. A., & Ladenson, P. W. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.7.2153 · Cited by 71 · see citing works

Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients

Liu, L., Yu, Y., Zhao, M., Zheng, D., Zhang, X., Guan, Q., Xu, C., Gao, L., Zhao, J., & Zhang, H. (2017) · International Journal of Endocrinology · doi:10.1155/2017/5753039 · Cited by 71 · see citing works

Thyroid hormone protects hepatocytes from HBx-induced carcinogenesis by enhancing mitochondrial turnover

Chi, H.-C., Chen, S.-L., Lin, S.-L., Tsai, C.-Y., Chuang, W.-Y., Lin, Y.-H., Huang, Y.-H., Tsai, M.-M., Yeh, C.-H., & Lin, K.-H. (2017) · Oncogene · doi:10.1038/onc.2017.136 · Cited by 70 · see citing works

The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial

Sabag, A., Way, K. L., Sultana, R. N., Keating, S. E., Gerofi, J. A., Chuter, V., Byrne, N. M., Baker, M. K., George, J., Caterson, I. D., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2523 · Cited by 67 · see citing works

Thyroid stimulating hormone increases hepatic gluconeogenesis via CRTC2

Li, Y., Wang, L., Zhou, L., Song, Y., Ma, S., Yu, C., Zhao, J., Xu, C., & Gao, L. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.015 · Cited by 61 · see citing works

Thyroid hormone suppresses hepatocarcinogenesis via DAPK2 and SQSTM1-dependent selective autophagy

Chi, H., Chen, S. L., Tsai, C., Chuang, W., Huang, Y.-H., Tsai, M.-M., Wu, S., Sun, C., Yeh, C., & Lin, K. (2016) · Autophagy · doi:10.1080/15548627.2016.1230583 · Cited by 60 · see citing works

A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia

Zhou, J., Waskowicz, L. R., Lim, A., Liao, X.-H., Lian, B., Masamune, H., Refetoff, S., Tran, B., Koeberl, D. D., & Yen, P. M. (2019) · Thyroid® · doi:10.1089/thy.2019.0007 · Cited by 60 · see citing works

Thyroid hormone receptor β mutants: Dominant negative regulators of peroxisome proliferator-activated receptor γ action

Araki, O., Ying, H., Furuya, F., Zhu, X., & Cheng, S.-Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508556102 · Cited by 57 · see citing works

Novel thyroid hormone analogues, enzyme inhibitors and mimetics, and their action

Mondal, S., & Mugesh, G. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.04.006 · Cited by 57 · see citing works

Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver‐selective thyroid hormone receptor agonist eprotirome

Angelin, B., Kristensen, J. D., Eriksson, M., Carlsson, B., Klein, I. L., OLSSON, A. G., Ridgway, E. C., & Ladenson, P. W. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12261 · Cited by 55 · see citing works

Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta

Chaves, C., Bruinstroop, E., Refetoff, S., Yen, P. M., & Anselmo, J. (2021) · Thyroid® · doi:10.1089/thy.2020.0651 · Cited by 55 · cited 1× · see citing works

L-Thyroxine contamination of pharmaceutical D-thyroxine: Probable cause of therapeutic effect

Young, W. F., Gorman, C. A., Jiang, N., Machacek, D., & HAY, I. D. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.257 · Cited by 54 · see citing works

Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression

Bruinstroop, E., Zhou, J., Tripathi, M., Yau, W. W., Boelen, A., Singh, B., & Yen, P. (2021) · bioRxiv · doi:10.1016/j.molmet.2021.101266 · Cited by 52 · see citing works

MED1 mediator subunit is a key regulator of hepatic autophagy and lipid metabolism

Zhou, J., Singh, B. K., Ho, J. P., Lim, A. R., Bruinstroop, E., Ohba, K., Sinha, R. A., & Yen, P. M. (2021) · Autophagy · doi:10.1080/15548627.2021.1899691 · Cited by 48 · see citing works

Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications

Kizivat, T., Marić, I., Mudri, D., Bilić-Čurčić, I., Primorac, D., & Smolić, M. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00027 · Cited by 47 · see citing works

Thyroid hormone analogues and derivatives: Actions in fatty liver

Coppola, M. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i3.114 · Cited by 46 · see citing works

Thyroid hormone β receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys

Ito, B., Zhang, B. L., Cable, E. E., Song, X., Fujitaki, J., MacKenna, D., Wilker, C., Chi, B., Poelje, P. V., Linemeyer, D., et al. (2009) · British Journal of Pharmacology · doi:10.1111/j.1750-3639.2009.00038.x · Cited by 44 · see citing works

The Thyroid Hormone Receptor-β Agonist GC-1 Induces Cell Proliferation in Rat Liver and Pancreas

Columbano, A., Pibiri, M., Deidda, M., Cossu, C., Scanlan, T. S., Chiellini, G., Muntoni, S., & Ledda‐Columbano, G. M. (2006) · Endocrinology · doi:10.1210/en.2005-1561 · Cited by 39 · see citing works

TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high‐fat diet

Cioffi, F., Zambad, S. P., Chhipa, L., Senese, R., Busiello, R. A., Tuli, D., Munshi, S., Moreno, M., Lombardi, A., Gupta, R. C., et al. (2010) · The FASEB Journal · doi:10.1096/fj.10-157115 · Cited by 39 · see citing works

Thyroid Stimulating Hormone Levels Are Associated With Genetically Predicted Nonalcoholic Fatty Liver Disease

Fan, H. X., Liu, Z., Zhang, X., Wu, S. L., Shi, T., Zhang, P., Xu, Y., Chen, X., & Zhang, T. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac393 · Cited by 39 · see citing works

Thyroid hormones induce activation of rat hepatic stellate cells through increased expression of p75 neurotrophin receptor and direct activation of Rho

Zvibel, I., Atias, D., Phillips, A. T., Halpern, Z., & Oren, R. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.48 · Cited by 37 · see citing works

Thyroid Hormone Regulates Hepatic Triglyceride Mobilization and Apolipoprotein B Messenger Ribonucleic Acid Editing in a Murine Model of Congenital Hypothyroidism

Mukhopadhyay, D., Plateroti, M., Anant, S., Nassir, F., Samarut, J., & Davidson, N. O. (2003) · Endocrinology · doi:10.1210/en.2002-220741 · Cited by 35 · see citing works

The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials

Angelidi, A. M., Papadaki, A., Nolen‐Doerr, E., Boutari, C., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155136 · Cited by 34 · see citing works

Biomarkers indicating tissue thyroid hormone status: ready to be implemented yet?

Jansen, H. I., Bruinstroop, E., Heijboer, A. C., & Boelen, A. (2022) · Journal of Endocrinology · doi:10.1530/joe-21-0364 · Cited by 33 · see citing works

Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future

Delitala, A. P., Delitala, G., Sioni, P., & Fanciulli, G. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1330259 · Cited by 29 · see citing works

The resurgence of thyromimetics as lipid-modifying agents.

Tancevski, I., Eller, K., Patsch, J. R., & Ritsch, A. (2009) · PubMed · Cited by 29 · see citing works

Human Stearoyl-CoA Desaturase 1 (SCD-1) Gene Expression Is Negatively Regulated by Thyroid Hormone without Direct Binding of Thyroid Hormone Receptor to the Gene Promoter

Hashimoto, K., Ishida, E., Miura, A., Ozawa, A., Shibusawa, N., Satoh, T., Okada, S., Yamada, M., & Mori, M. (2012) · Endocrinology · doi:10.1210/en.2012-1559 · Cited by 25 · see citing works

Sensitivity to thyroid hormones is associated with advanced fibrosis in euthyroid patients with non-alcoholic fatty liver disease: A cross-sectional study

Li, R., Zhou, L., Chen, C., Han, X., Gao, M., Cheng, X., & Li, J. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.06.021 · Cited by 22 · see citing works

Plasma proteome profiles treatment efficacy of incretin dual agonism in diet‐induced obese female and male mice

Sachs, S., Niu, L., Geyer, P. E., Jall, S., Kleinert, M., Feuchtinger, A., Stemmer, K., Brielmeier, M., Finan, B., DiMarchi, R. D., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14215 · Cited by 21 · see citing works

What is the Role of Thyroid Hormone Receptor Alpha 2 (TRα2) in Human Physiology?

Paisdzior, S., Schuelke, M., & Krude, H. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1716-7980 · Cited by 9 · see citing works

Comparative Analysis of the Effects of Long-Term 3,5-diiodothyronine Treatment on the Murine Hepatic Proteome and Transcriptome Under Conditions of Normal Diet and High-Fat Diet

Lietzow, J., Golchert, J., Pietzner, M., Völker, U., POUTANEN, M. H., Ohlsson, C., Homuth, G., & Köhrle, J. (2021) · Thyroid · doi:10.1089/thy.2020.0160 · Cited by 7 · see citing works

Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes

Gancheva, S., KAHL, S., Pesta, D. H., Mastrototaro, L., Dewidar, B., Straßburger, K., Sabah, E., Esposito, I., Weiß, J., Sarabhai, T., et al. (2022) · doi:10.2337/figshare.18409844.v1 · Cited by 2 · see citing works

The withdrawal of the thyromimetic eprotirome

France, M. W. (2014) · Clinical Lipidology · doi:10.2217/clp.14.29 · Cited by 1 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association

Cusi, K. J., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 396 · see citing works

An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease

Lee, E., Korf, H., & Vidal‐Puig, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.024 · Cited by 228 · see citing works

The first MASH drug therapy on the horizon: Current perspectives of resmetirom

Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. (2024) · Liver international (Print) · doi:10.1111/liv.15930 · Cited by 174 · see citing works

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies

Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 77 · see citing works

Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis

Suvarna, R., Shetty, S., & Pappachan, J. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-70242-8 · Cited by 66 · see citing works

The Role of Exercise in Steatotic Liver Diseases: An Updated Perspective

Razzak, I. A., Fares, A., Stine, J. G., & Trivedi, H. D. (2024) · Liver International · doi:10.1111/liv.16220 · Cited by 46 · see citing works

Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease

Weiskirchen, R., & Lonardo, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199594 · Cited by 36 · see citing works

Resmetirom: The First Disease‐Specific Treatment for MASH

Mousa, A. M., Mahmoud, M., & AlShuraiaan, G. M. (2025) · International Journal of Endocrinology · doi:10.1155/ije/6430023 · Cited by 34 · see citing works

Associations of phthalates with NAFLD and liver fibrosis: A nationally representative cross-sectional study from NHANES 2017 to 2018

Chen, X., Tian, F., Wu, J., Liu, L., Li, Y., Yu, G., Duan, H., Jiang, Y., Liu, S. M., He, Y., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1059675 · Cited by 32 · see citing works

Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon

Byrne, C. D., Targher, G., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2023-330596 · Cited by 30 · see citing works

Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD

Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 33 · see citing works

Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions

Abdel-Rasol, M. A., & El-Sayed, W. M. (2025) · European journal of medical research · doi:10.1186/s40001-025-03073-6 · Cited by 27 · see citing works

Review of current and new drugs for the treatment of metabolic-associated fatty liver disease

Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 24 · see citing works

Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD

Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 22 · see citing works

The central role of mitochondrial metabolism in hepatic steatosis

Win, S., Than, T. A., Kaplowitz, N., Wong, N., Arya, A., Win, Z. T., Win, S. H., Phyu, E., Kuemerle, C., Suh, J., et al. (2024) · Exploration of Digestive Diseases · doi:10.37349/edd.2024.00039 · Cited by 18 · see citing works

The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort

Feng, Q., Izzi‐Engbeaya, C. N., Branch, A. D., Mullish, B. H., Manousou, P., & Woodward, M. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf342 · Cited by 17 · see citing works

Association between non-alcoholic fatty liver disease and subclinical hypothyroidism in children with obesity

Sessa, A. D., Sanseverino, N. C. S., Simone, R. F. D., Marrapodi, M. M., Cirillo, G., Umano, G. R., Guarino, S., Papparella, A., del Giudice, E. M., & Marzuillo, P. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02041-3 · Cited by 17 · see citing works

Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment

Pu, S., Zhao, B., Jiang, Y., & Cui, X. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02474-0 · Cited by 19 · see citing works

Endocrine Disorders and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review

Betlejewska, J., Hubska, J., Roszkowska, Z., Maciejczyk, A., Bachurska, D., Domański, J., Miarka, M., Raszeja‐Wyszomirska, J., Bobrowicz, M., & Ambroziak, U. (2025) · Biomedicines · doi:10.3390/biomedicines13102500 · Cited by 19 · see citing works

Thyroid function, adipokines and mitokines in metabolic dysfunction‐associated steatohepatitis: A multi‐centre biopsy‐based observational study

Kouvari, M., Valenzuela‐Vallejo, L., Axarloglou, E., Verrastro, O., Papatheodoridis, G., Mingrone, G., George, J., & Mantzoros, C. S. (2024) · Liver International · doi:10.1111/liv.15847 · Cited by 16 · see citing works

Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study

Untalan, M., Crimmins, N. A., Yates, K. P., Mencin, A., Xanthakos, S. A., & Thaker, V. (2024) · Hepatology · doi:10.1097/hep.0000000000001095 · Cited by 16 · see citing works

Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier

Tiwari, A., Sharma, A., Kumar, H., Gupta, V., Deshpande, V., Mupparaju, J. S., Mishra, T., Bharadwaj, H. R., Dahiya, D. S., & Jain, V. (2025) · Biomedicines · doi:10.3390/biomedicines13092079 · Cited by 17 · see citing works

Generation and characterization of mature hepatocyte organoids for liver metabolic studies

Liu, Y., Zhou, Y., Ahodantin, J., Jin, Y., Zhu, J., Sun, Z., Wu, X., Su, L., & Yang, Y. (2024) · Journal of Cell Science · doi:10.1242/jcs.261961 · Cited by 15 · see citing works

Mitochondria at the Crossroads: Linking the Mediterranean Diet to Metabolic Health and Non-Pharmacological Approaches to NAFLD

Mercurio, G., Giacco, A., Scopigno, N., Vigliotti, M., Goglia, F., Cioffi, F., & Silvestri, E. (2025) · Nutrients · doi:10.3390/nu17071214 · Cited by 14 · see citing works

Targeting Metabolism: Innovative Therapies for MASLD Unveiled

Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 14 · see citing works

Gut microbiota-mitochondrial crosstalk in obesity: novel mechanistic insights and therapeutic strategies with traditional Chinese medicine

Wen, L., Yang, K., Wang, J., Zhou, H., & Ding, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574887 · Cited by 14 · see citing works

Fibrosis status, extrahepatic multimorbidity and all-cause mortality in 53,093 women and 74,377 men with metabolic dysfunction associated steatotic liver disease (MASLD) in UK biobank

Feng, Q., Izzi‐Engbeaya, C. N., Manousou, P., & Woodward, M. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04079-4 · Cited by 12 · see citing works

Association of thyroid function with non‐alcoholic fatty liver disease in recent‐onset diabetes

Saatmann, N., Schön, M., Zaharia, O., Huttasch, M., Straßburger, K., Trenkamp, S., Kupriyanova, Y., Schrauwen‐Hinderling, V. B., KAHL, S., Burkart, V., et al. (2023) · Liver International · doi:10.1111/liv.15723 · Cited by 11 · see citing works

Interplay between endocrine disorders and liver dysfunction: Mechanisms of damage and therapeutic approaches

Vargas-Beltran, A. M., Armendariz-Pineda, S. M., Martínez‐Sánchez, F. D., Martinez-Perez, C., Torre, A., & Córdova‐Gallardo, J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i32.108827 · Cited by 10 · see citing works

Targeting THR-β for MASLD Treatment: Current Progression and Emerging Prospects

Li, J., Chen, R., Zhang, J., He, J., Wang, Y., & Li, Y. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03114 · Cited by 11 · see citing works

Daphnetin ameliorates hepatic steatosis by suppressing peroxisome proliferator-activated receptor gamma (PPARG) in ob/ob mice

Wang, Z., Gao, P., Gao, J., Liang, B., Ma, Q., Sun, Q., Hu, Y., Wang, Y., Peng, Y., Liu, H., et al. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116610 · Cited by 9 · see citing works

Liver fibrotic burden across the spectrum of hypothyroidism

Du, T., Huang, Y., Lv, Y., & Yuan, G. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02184-x · Cited by 9 · see citing works

Exploring the nexus between hypothyroidism and metabolic dysfunction-associated steatotic liver disease: a UK biobank cohort study

Wang, H., Zheng, C., & Wang, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-91221-7 · Cited by 8 · see citing works

Thyrotropin exacerbates insulin resistance by triggering macrophage inflammation in subclinical hypothyroidism

Zhang, H., Zeng, Z., Liu, Y., Zheng, W., Wang, J., Yao, Y., Wang, Y., Ji, M., & Hou, P. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01478-1 · Cited by 8 · see citing works

Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study

Huang, D. Q., Tran, S., Barnett, S. D., Zou, B., Yeo, Y. H., Cheung, R. C., & Nguyen, M. H. (2023) · Hepatology International · doi:10.1007/s12072-023-10616-8 · Cited by 8 · see citing works

Efficacy and safety of resmetirom for the treatment of nonalcoholic steatohepatitis: a GRADE assessed systematic review and meta-analysis

Talha, M., Ali, M. H., Nadeem, Z. A., Akram, U., Saravanan, P. B., & Khalid, M. H. A. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002892 · Cited by 7 · see citing works

Thyroid dysfunction in MASLD: Results of a nationwide study

Yuan, S., Ebrahimi, F., Bergman, D., Vujković, M., Scorletti, E., Ruan, X., Chen, J., Hagström, H., & Ludvigsson, J. F. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101369 · Cited by 7 · see citing works

An extended transcription factor regulatory network controls hepatocyte identity

Dubois‐Chevalier, J., Gheeraert, C., Berthier, A., Boulet, C., Dubois, V., Guille, L., Fourcot, M., Marot, G., Gauthier, K., Dubuquoy, L., et al. (2023) · EMBO Reports · doi:10.15252/embr.202357020 · Cited by 6 · see citing works

Intestinal deguelin drives resistance to acetaminophen-induced hepatotoxicity in female mice

Gong, S., Zeng, Y., Wang, Z., Li, Y., Wu, R., Li, L., Hu, H., Qin, P., Yu, Z., Huang, X., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2404138 · Cited by 6 · see citing works

Association of exposure to multiple volatile organic compounds with ultrasound-defined hepatic steatosis and fibrosis in the adult US population: NHANES 2017–2020

Shao, W., Gong, P., Wang, Q., Ding, F., Shen, W., Zhang, H., Huang, A., & Liu, C. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1437519 · Cited by 6 · see citing works

Development and validation of a nomogram-based risk prediction model for non-alcoholic fatty liver disease (NAFLD): a logistic regression analysis in a physical examination population

Lan, J. Q., Que, T., Lan, H., Zhang, M., & Ban, L. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04115-3 · Cited by 5 · see citing works

ECM remodeling in hypothyroidism-associated MAFLD: mechanisms, clinical relevance, and therapeutic targets

Wang, T., Duan, L., Zhao, B., Zhang, J., Yu, Y., & Zhao, J.-Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639196 · Cited by 6 · see citing works

Evidence on the link between hypothyroidism and non-alcoholic fatty liver disease: an updated systematic review

Pourseyedi, N., Arefhosseini, S., Tutunchi, H., & Ebrahimi‐Mameghani, M. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01977-2 · Cited by 6 · see citing works

Palmitoylation in cardiometabolic diseases: From molecular mechanisms to clinical implications

Feng, S., Zhou, Y. X., Guo, L., Liang, Y., & Zhu, W. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107921 · Cited by 5 · see citing works

Sex-Specific Associations Between Organophosphate Esters Metabolites and Metabolic Dysfunction-Associated Fatty Liver Disease in Chinese Adults

Liu, Q., Fan, G., Bi, J., Qin, X., Fang, Q., Wu, M., Mei, S., Wan, Z., Lv, Y., Wang, Y., et al. (2024) · Exposure and Health · doi:10.1007/s12403-024-00629-5 · Cited by 4 · see citing works

Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy

Habib, S. (2024) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v15.i4.93606 · Cited by 4 · see citing works

Exploration of Digestive Diseases

(2022) · Exploration of Digestive Diseases · doi:10.37349/edd · Cited by 4 · see citing works

Relationship Between Thyroid Hormones and Fat Distribution in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

Yang, J., Gao, C., Wan, Q., & Xu, Y. J. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s541859 · Cited by 3 · see citing works

Thyroid‐Liver Axis: The Role of Thyroid Dysfunction in the Pathogenesis and Progression of MASLD: A Comprehensive Review

Capuccio, S., Privitera, G., Scilletta, S., Rocca, F. L., Marco, M. D., Scicali, R., Pino, A. D., Piro, S., & Russello, M. (2026) · Liver international (Print) · doi:10.1111/liv.70431 · Cited by 4 · see citing works

Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review

Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 3 · see citing works

Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis

Wang, Y., Yu, H., Cen, Z., Zhu, Y., & Wu, W. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100267 · Cited by 3 · see citing works

Endocrinology for the Hepatologist

Isaacs, S. D., & Isaacs, A. (2024) · Current Hepatology Reports · doi:10.1007/s11901-024-00639-6 · Cited by 3 · see citing works

Institutional Nomogram for Estimating Risk of Metabolic Associated Fatty Liver Disease (MAFLD)

Lv, T.-S., Tian, J., Sun, Y., Zhang, Y., Qi, F., Xiang, L.-L., Cao, Y.-T., Zhang, W., Huai, J., Dong, Y., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s469677 · Cited by 2 · see citing works

Clinical Characteristics, Risk Factors, and Predictors of Nonobese Fatty Liver Disease: A Cross-Sectional Study

Zhang, X., Wang, S., Xu, S., Min, R., Ling, Y., Sun, S., & Gong, R. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s482638 · Cited by 2 · see citing works

d4-Cystamine: A Deuterated Cystamine Derivative with Improved Anti-Inflammatory and Anti-Fibrotic Activities in a Murine Model of Fibrosing Steatohepatitis

Leszczynska, A., Alle, T., Kaufmann, B. K., Sung, H., Stoess, C., Reca, A., Kim, A. D., Kim, S., Tran, C., Oukoloff, K., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00738 · Cited by 2 · see citing works

Targeting THR-β for MASLD: Mechanisms and Drug Development

Hua, Y., Liu, Y., Xing, L.-J., Yu, X., Zheng, P.-Y., Yang, L., & Song, H.-Y. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s558221 · Cited by 4 · see citing works

Non-alcoholic fatty liver disease in patients with type 2 diabetes: diagnostic and therapeutic considerations

Paraschou, E., Shalit, A., & Paschou, S. Α. (2023) · HORMONES · doi:10.1007/s42000-023-00514-x · Cited by 2 · see citing works

Hypothyroidism impairs the circadian rhythmicity of clock genes and proteins involved in gut nutrient absorption in female mice

Secio‐Silva, A., Evangelista-Silva, P. H., Emrich, F., Selvatici‐Tolentino, L., Ferreira, M., Silva, A. B. D. P., Gomes, B. H., da Costa, T. N. F., de Oliveira, A. G., Garcia, R. A. P., et al. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1515437 · Cited by 2 · see citing works

Correlation Between Thyroid-Stimulating Hormone (TSH) and Liver Function Test Values in North Karnataka Patients Admitted to a Tertiary Care Hospital

Krishna, S. M., Hegde, S. V., Chellathurai, M., Mohandas, N. J. A., Guruswamy, S., Pandit, S., Afra, A., Shetty, S., & Siripuram, C. (2024) · Cureus · doi:10.7759/cureus.59004 · Cited by 1 · see citing works

Visceral adipocyte metabolic dysfunction in obesity related to altered chromatin accessibility to thyroid hormone receptor

Zhu, H., Zhang, J., Ma, Z.-W., Zhang, W.-N., Yang, Y., Lu, X.-B., Gan, C., Guo-xian, D., Yu, J., Duan, Y., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149554 · Cited by 1 · see citing works

Discovery of a Potent, Selective, and Multiple His435 Mutation-Sensitive Thyroid Hormone Receptor β Agonist

Li, Q., Yao, B., Zhao, S., Lu, Z., Wu, X., Lu, Z.-F., Wu, T., Li, J., Chen, X., Chen, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00164 · Cited by 1 · see citing works

The association between gestational hypothyroidism in pregnant women with preeclampsia, maternal liver function indicators, and neonatal birth weight: a study in Chinese pregnant women

Zhang, F., Hua, Q., You, X., Shi, F., Zhou, Y., Xu, X., Tian, X., Tian, G., & Li, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1555277 · Cited by 1 · see citing works

Significant association of sensitivity to thyroid hormones with liver fibrosis: Analysis based on NHANES data

Zhao, Y., Wu, X.-Q., Luo, P., & Liao, S.-L. (2025) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2025.09.001 · Cited by 1 · see citing works

Resmetirom: a first-in-class thyroid hormone receptor β agonist approved by FDA for patients with nonalcoholic steatohepatitis

Wu, X., Xiang, Q., Zhang, Y., & Xu, Y. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00026-3 · Cited by 1 · see citing works

Raman spectroscopic characterization of liver steatosis and fibrosis in a 2D and 3D in vitro thyroxine-treated hypothyroid cellular model

Maurotti, S., Scopacasa, B., Scionti, F., Pujia, R., Frosina, M., Mirarchi, A., Geirola, N., Mare, R., Montalcini, T., Candeloro, P., et al. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112679 · Cited by 1 · see citing works

Thyroid dysfunction in liver pathology

Uryasev, O. M., Solovieva, A. V., Берстнева, С. В., & Slabachkov, K. O. (2025) · I P Pavlov Russian Medical Biological Herald · doi:10.17816/pavlovj634239 · Cited by 1 · see citing works

Protective effect of higher free thyroxine levels within the reference range on biliary tract cancer risk: a multivariable mendelian randomization and mediation analysis

Chen, Y., Dong, H., Qu, B., Ma, X., & Lu, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1379607 · Cited by 1 · see citing works

Increased risk of nonalcoholic fatty liver disease in patients with thyroid cancer: a nationwide cohort study

Cho, Y. B., & Park, K. S. (2025) · BMC Cancer · doi:10.1186/s12885-025-14485-2 · Cited by 1 · see citing works

Fibrosis status, extra-hepatic multimorbidity and all-cause mortality in 53093 women and 74377 men with MASLD in UK BiobankPreprint

Feng, Q., Izzi‐Engbeaya, C. N., Manousou, P., & Woodward, M. (2025) · medRxiv · doi:10.1101/2025.03.09.25323329 · Cited by 1 · see citing works

Decabromodiphenyl Ethane Interferes with Unfolded Protein Response to Disrupt Thyroid FunctionPreprint

Yang, X., Liang, B., Hou, M., Jing, L., & Shi, Z. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4865420

Age-Related Enhancement of HPT Axis Sensitivity to Thyroid Hormones Protects Metabolic and Cardiovascular HealthPreprint

Zhao, L., Mu, R., Zhang, X., Wang, S., Zhao, M., & Shang, H. (2025) · Research Square · doi:10.21203/rs.3.rs-6780346/v1

Novel thyroid hormone receptor-β1 agonist in the treatment of MASH

Overholser, A., & Czech, E. J. (2025) · JAAPA · doi:10.1097/01.jaa.0000000000000237

Association of environmental water iodine concentration with abnormal circulating liver function indicators in a cross-sectional chinese population study

Chen, Y., Bai, X., He, Y., Che, W., Zhou, Z., Gao, H., Zhang, Y., Chen, Y., Jia, Q., Liu, L., et al. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118767

Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASHPreprint

Mardinoğlu, A., Kim, W., Li, M., Liao, X., Özmen, S., Yıldız, E., Saraçoğlu, M., Baba, C., Çelikezen, F. Ç., Atalay, S. A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7114368/v1

Sex-Stratified Prediction Models for 5-Year Nonalcoholic Fatty Liver Disease Risk in Thyroid Cancer Patients: A Nationwide Cohort Study

Cho, Y. B., & Park, K. S. (2025) · Biomedicines · doi:10.3390/biomedicines13092250

Prognostic significance of preoperative thyroid hormone sensitivity status for recurrence in papillary thyroid carcinoma

Li, C., Li, S., Zhao, Y., Zhang, D., Fu, Y., Zhou, L., Li, J., Li, F., Du, R., Liang, N., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag044

A potential therapeutic effect of 84-B10 in MASLD through promotion of FASN degradation

Bai, Y.-P., Yin, Y., Wang, S.-M., Chen, J., Zhang, Z., Zhu, Z.-Q., Shao, G.-X., Zhu, Y., Jiang, Y.-Y., Sun, B.-C., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01745-x

Signal Amplification in the HPT Axis—Evidence for Its Existence, Location, Significance, and Molecular Mechanisms

Li, J., Moyd, S. A., & Zhang, Q. (2026) · Acta Physiologica · doi:10.1111/apha.70202

Rôle de REG3A dans la maladie métabolique du foie d'origine nutritionnelle

Nguyen, T.-S. (2024) · theses.fr (ABES) · doi:10.70675/2c0ffdcfz96ccz43b0z8e03zb358f83e528d

Novel Biomarkers for Assessing the Risk of Cardiovascular Disease in Individuals with Thyroid Dysfunction: Non-High-Density Lipoprotein Cholesterol Versus Non-High-Density Lipoprotein Cholesterol/High-Density Lipoprotein Cholesterol Ratio

Omon, E. A., Ajayi, O. D., Edet, O. O., & Airhomwanbor, K. O. (2026) · Journal of Cardiac Critical Care TSS · doi:10.25259/jccc_55_2025

Effects and mechanisms of low-dose decabromodiphenyl ethane exposure on thyroid hormone homeostasis disruption

Yang, X., Chen, Y., Liang, B., Hou, M., Li, J., & Shi, Z. (2026) · Journal of Environmental Sciences · doi:10.1016/j.jes.2026.04.045

Novel Approaches to Diagnosing and Treating Non-alcoholic Fatty Liver Disease: Opportunities and Accomplishments

Uzyanbaev, I. A., Timoshenko, S., Спирина, Л. В., & Матвеева, М. В. (2026) · Current Drug Targets · doi:10.2174/0113894501398066251211070417

Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort

Cho, H. J., Kang, S. H., Chon, H. Y., Bae, S., Kim, E., Na, S. K., Kim, S. J., Kim, D., Ahn, H. R., Kim, H., et al. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e258

Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH

Kim, W., Li, M., Liao, X., Özmen, S., Yıldız, E., Saraçoğlu, M., Baba, C., Çelikezen, F. Ç., Atalay, S. A., Akkuş, A. T., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1823203

ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial

Loomba, R. S., Wang, S., Desai, D., Santillano, D., Lucas, K. J., Neff, G., Bianco, A. C., Bruinstroop, E., Su, Y., Achneck, H. E., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00154-8

Long-term metabolic risks after thyroidectomy and thyroid hormone therapy in thyroid cancer survivors: a nationwide cohort study

Lee, J., Kim, C. H., Kim, Y., Ha, Y., Choi, Y. M., & Park, B. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1845515

Age-related changes in HPT axis sensitivity and their associations with metabolic and cardiovascular health: a cross-sectional, Chinese nationwide study

Zhao, L., Mu, R., Zhang, X., Wang, S., Zhao, M., & Shang, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1857191

Hypothyroidism and Metabolic Dysfunction–Associated Steatotic Liver Disease: Mechanisms, Clinical Links, and Therapeutic Implications

Qadir, A. M., & Omer, R. A. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00764-x

An overview of the consequences of subclinical hypothyroidism

Mach, T., & Yu, O. H. Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30261-9.00004-8

Associations of early-pregnancy triiodothyronine and triglycerides with hypertensive disorders of pregnancy: a retrospective cohort study

Li, Y., Ren, J., Yang, S., Zhou, Y., Huang, Z., Lv, S., Wu, W., & 范建霞 (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1975129

Disfunción tiroidea, hipertrigliceridemia e hipertensión como eje cardiometabólico: revisión sistemática de los mecanismos fisiopatológicos y la evidencia clínica (2021–2026)

Contreras, F. C. J., Guamán, R. N. G., Huilca, S. I., Urbano, J. J. Ñ., & Romo, M. S. S. (2026) · ASCE MAGAZINE · doi:10.70577/asce.v5i4.1129

Thyroid dysfunction and non-alcoholic fatty liver disease

Efstathiadou, Z. A., Kita, M. D., & Pοlyzos, S. A. (2018) · Minerva Endocrinology · doi:10.23736/s0391-1977.17.02617-7 · Cited by 17 · see citing works

Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease

Vidal‐Cevallos, P., Gall, S. M.-B., Uribe, M., & Chávez-Tapia, N. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914605 · Cited by 51 · see citing works

Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options

Tănase, D. M., Gosav, E. M., Neculae, E., Costea, C. F., Ciocoiu, M., Hurjui, L. L., Tărniceriu, C. C., & Floria, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165927 · Cited by 66 · see citing works

Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications

Kizivat, T., Marić, I., Mudri, D., Bilić-Čurčić, I., Primorac, D., & Smolić, M. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00027 · Cited by 47 · see citing works

Cross-talk between the thyroid and liver: A new target for nonalcoholic fatty liver disease treatment

Huang, Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i45.8238 · Cited by 36 · see citing works